Cargando…
1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections
BACKGROUND: SPR720 (phosphate pro-drug of SPR719) is a novel aminobenzimidazole bacterial DNA gyrase (GyrB) inhibitor in development for non-tuberculous mycobacterial lung disease (NTM-LD) and pulmonary tuberculosis. SPR719 has broad-spectrum activity versus clinically relevant mycobacteria in vitro...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777491/ http://dx.doi.org/10.1093/ofid/ofaa439.1471 |
_version_ | 1783630914208661504 |
---|---|
author | Talley, Angela Thurston, Archie Moore, Grayson Satterfield, Myriah M Manyak, Erika L Kumar, Vipul Stokes, Suzanne Dane, Aaron Melnick, David |
author_facet | Talley, Angela Thurston, Archie Moore, Grayson Satterfield, Myriah M Manyak, Erika L Kumar, Vipul Stokes, Suzanne Dane, Aaron Melnick, David |
author_sort | Talley, Angela |
collection | PubMed |
description | BACKGROUND: SPR720 (phosphate pro-drug of SPR719) is a novel aminobenzimidazole bacterial DNA gyrase (GyrB) inhibitor in development for non-tuberculous mycobacterial lung disease (NTM-LD) and pulmonary tuberculosis. SPR719 has broad-spectrum activity versus clinically relevant mycobacteria in vitro and in murine and hollow fiber (HF) infection models. In this first-in-human single ascending dose (SAD) /multiple ascending dose (MAD) study, the safety, tolerability and pharmacokinetics (PK) of SPR720/SPR719 were evaluated in healthy volunteers. METHODS: This was a Phase 1 randomized, double-blind, placebo-controlled trial with 7 SAD cohorts (including a food effect cohort) and 5 MAD cohorts. Healthy volunteers (n=8/cohort, 3:1 randomization) received SPR720 or placebo in single oral doses of ranging from 100 mg to 2000 mg or repeat total daily doses ranging from 500 mg to 1500 mg for 7 or 14 days. Safety monitoring and PK sampling occurred throughout the trial. Plasma and urine concentrations of SPR720/SPR719 were measured by validated LC-MS/MS methods. PK parameters were calculated using non-compartmental analysis. RESULTS: A total of 96 subjects (including 8 healthy elderly subjects, age ≥ 65 years) were randomized and received study drug. SPR720 was well-tolerated at daily doses up to 1000 mg for up to 14 days. Across SAD/MAD cohorts, the most common adverse events were gastrointestinal (nausea, vomiting and diarrhea) and headache, all of mild or moderate severity and dose dependent. No serious adverse events were reported. Across SAD cohorts, a dose proportional and greater-than-dose proportional increase in SPR719 plasma C(max) and AUC(0-24), respectively were observed. SPR720 was rapidly absorbed with a mean SPR719 t(1/2) of 2.9-4.5 h. Dosing with food decreased SPR719 plasma AUC by ~20%. No clinically meaningful effect of age on plasma AUC was observed. In the MAD cohorts, SPR719 plasma exposure declined approximately 40% between Day 1 and Day 7, suggesting induction of an elimination pathway. However, plasma AUC(0-24) was similar at Days 7 and 14. CONCLUSION: Together with HF pharmacodynamic data, human PK and safety data for SPR720 suggest that predicted therapeutic exposures can be attained with a well-tolerated once-daily dose. Further evaluation in a Phase 2 NTM-LD trial is planned. DISCLOSURES: Angela Talley, MD, Spero Therapeutics (Employee, Shareholder) Archie Thurston, Jr., PhD, Spero Therapeutics (Consultant) Grayson Moore, BA, RN, Spero Therapeutics, Inc. (Shareholder, Independent Contractor) Vipul Kumar, PhD, Spero Therapeutics (Employee, Shareholder) Suzanne Stokes, PhD, Spero Therapeutics (Employee, Shareholder) Aaron Dane, MSc, Spero theraputics (Consultant) David Melnick, MD, Spero Therapeutics (Employee)Spero Therapeutics (Employee) |
format | Online Article Text |
id | pubmed-7777491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77774912021-01-07 1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections Talley, Angela Thurston, Archie Moore, Grayson Satterfield, Myriah M Manyak, Erika L Kumar, Vipul Stokes, Suzanne Dane, Aaron Melnick, David Open Forum Infect Dis Poster Abstracts BACKGROUND: SPR720 (phosphate pro-drug of SPR719) is a novel aminobenzimidazole bacterial DNA gyrase (GyrB) inhibitor in development for non-tuberculous mycobacterial lung disease (NTM-LD) and pulmonary tuberculosis. SPR719 has broad-spectrum activity versus clinically relevant mycobacteria in vitro and in murine and hollow fiber (HF) infection models. In this first-in-human single ascending dose (SAD) /multiple ascending dose (MAD) study, the safety, tolerability and pharmacokinetics (PK) of SPR720/SPR719 were evaluated in healthy volunteers. METHODS: This was a Phase 1 randomized, double-blind, placebo-controlled trial with 7 SAD cohorts (including a food effect cohort) and 5 MAD cohorts. Healthy volunteers (n=8/cohort, 3:1 randomization) received SPR720 or placebo in single oral doses of ranging from 100 mg to 2000 mg or repeat total daily doses ranging from 500 mg to 1500 mg for 7 or 14 days. Safety monitoring and PK sampling occurred throughout the trial. Plasma and urine concentrations of SPR720/SPR719 were measured by validated LC-MS/MS methods. PK parameters were calculated using non-compartmental analysis. RESULTS: A total of 96 subjects (including 8 healthy elderly subjects, age ≥ 65 years) were randomized and received study drug. SPR720 was well-tolerated at daily doses up to 1000 mg for up to 14 days. Across SAD/MAD cohorts, the most common adverse events were gastrointestinal (nausea, vomiting and diarrhea) and headache, all of mild or moderate severity and dose dependent. No serious adverse events were reported. Across SAD cohorts, a dose proportional and greater-than-dose proportional increase in SPR719 plasma C(max) and AUC(0-24), respectively were observed. SPR720 was rapidly absorbed with a mean SPR719 t(1/2) of 2.9-4.5 h. Dosing with food decreased SPR719 plasma AUC by ~20%. No clinically meaningful effect of age on plasma AUC was observed. In the MAD cohorts, SPR719 plasma exposure declined approximately 40% between Day 1 and Day 7, suggesting induction of an elimination pathway. However, plasma AUC(0-24) was similar at Days 7 and 14. CONCLUSION: Together with HF pharmacodynamic data, human PK and safety data for SPR720 suggest that predicted therapeutic exposures can be attained with a well-tolerated once-daily dose. Further evaluation in a Phase 2 NTM-LD trial is planned. DISCLOSURES: Angela Talley, MD, Spero Therapeutics (Employee, Shareholder) Archie Thurston, Jr., PhD, Spero Therapeutics (Consultant) Grayson Moore, BA, RN, Spero Therapeutics, Inc. (Shareholder, Independent Contractor) Vipul Kumar, PhD, Spero Therapeutics (Employee, Shareholder) Suzanne Stokes, PhD, Spero Therapeutics (Employee, Shareholder) Aaron Dane, MSc, Spero theraputics (Consultant) David Melnick, MD, Spero Therapeutics (Employee)Spero Therapeutics (Employee) Oxford University Press 2020-12-31 /pmc/articles/PMC7777491/ http://dx.doi.org/10.1093/ofid/ofaa439.1471 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Abstracts Talley, Angela Thurston, Archie Moore, Grayson Satterfield, Myriah M Manyak, Erika L Kumar, Vipul Stokes, Suzanne Dane, Aaron Melnick, David 1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections |
title | 1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections |
title_full | 1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections |
title_fullStr | 1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections |
title_full_unstemmed | 1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections |
title_short | 1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections |
title_sort | 1288. phase 1 first-in-human single- and multiple-ascending dose trial demonstrates pharmacokinetics (pk) and tolerability of spr720, an oral dna gyrb inhibitor for mycobacterial infections |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777491/ http://dx.doi.org/10.1093/ofid/ofaa439.1471 |
work_keys_str_mv | AT talleyangela 1288phase1firstinhumansingleandmultipleascendingdosetrialdemonstratespharmacokineticspkandtolerabilityofspr720anoraldnagyrbinhibitorformycobacterialinfections AT thurstonarchie 1288phase1firstinhumansingleandmultipleascendingdosetrialdemonstratespharmacokineticspkandtolerabilityofspr720anoraldnagyrbinhibitorformycobacterialinfections AT mooregrayson 1288phase1firstinhumansingleandmultipleascendingdosetrialdemonstratespharmacokineticspkandtolerabilityofspr720anoraldnagyrbinhibitorformycobacterialinfections AT satterfieldmyriahm 1288phase1firstinhumansingleandmultipleascendingdosetrialdemonstratespharmacokineticspkandtolerabilityofspr720anoraldnagyrbinhibitorformycobacterialinfections AT manyakerikal 1288phase1firstinhumansingleandmultipleascendingdosetrialdemonstratespharmacokineticspkandtolerabilityofspr720anoraldnagyrbinhibitorformycobacterialinfections AT kumarvipul 1288phase1firstinhumansingleandmultipleascendingdosetrialdemonstratespharmacokineticspkandtolerabilityofspr720anoraldnagyrbinhibitorformycobacterialinfections AT stokessuzanne 1288phase1firstinhumansingleandmultipleascendingdosetrialdemonstratespharmacokineticspkandtolerabilityofspr720anoraldnagyrbinhibitorformycobacterialinfections AT daneaaron 1288phase1firstinhumansingleandmultipleascendingdosetrialdemonstratespharmacokineticspkandtolerabilityofspr720anoraldnagyrbinhibitorformycobacterialinfections AT melnickdavid 1288phase1firstinhumansingleandmultipleascendingdosetrialdemonstratespharmacokineticspkandtolerabilityofspr720anoraldnagyrbinhibitorformycobacterialinfections |